Literature DB >> 31356972

Survival and Prognostic Predictors of Anaplastic Meningiomas.

Waseem Masalha1, Dieter Henrik Heiland2, Daniel Delev2, Jamina Tara Fennell3, Pamela Franco2, Christian Scheiwe2, Bianca-Ioana Mercas2, Irina Mader4, Oliver Schnell2, Juergen Grauvogel2.   

Abstract

BACKGROUND: Anaplastic meningiomas are rare tumors with a poor prognosis, even after complete surgical resection and radiotherapy. There has been limited evidence with respect to the clinical factors and their effects on the course of the disease. Various retrospective studies have not been able to provide clear evidence of standardized treatment, usually presenting contradictory results. The aim of this study was to evaluate the prognostic factors influencing the progression-free survival (PFS) and overall survival (OS) of anaplastic meningiomas, with a particular focus on the roles of the extent of resection and postoperative adjuvant radiotherapy.
METHODS: Between October 2001 and March 2016, 36 patients with anaplastic meningiomas were treated in our Department of Neurosurgery, of whom 11 underwent gross total resection (GTR) and 18 subtotal resection. Twenty-one patients received postoperative adjuvant radiotherapy, and 8 were treated with surgery alone. GTR (Simpson grades I and II) was associated with significantly improved PFS (P = 0.01) and OS (P = 0.004). Furthermore, adjuvant radiotherapy showed an improvement in PFS (P = 0.01) but not in OS (P = 0.16).
CONCLUSIONS: The extent of resection in anaplastic meningiomas is correlated with a better outcome. However, resection alone is not sufficient for the long-term control of anaplastic meningiomas. Adjuvant radiotherapy is an essential component in the adjuvant treatment of anaplastic meningiomas, including for patients undergoing GTR. Further investigations through which to improve adjuvant therapy options are necessary to improve meningioma therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adjuvant radiotherapy; Anaplastic meningiomas; Meningiomas; Surgery

Mesh:

Year:  2019        PMID: 31356972     DOI: 10.1016/j.wneu.2019.07.148

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

Review 1.  Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review.

Authors:  P D Delgado-López; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2020-07-10       Impact factor: 3.405

2.  Analysis of Prognostic Factors of World Health Organization Grade Ⅲ Meningiomas.

Authors:  Weidong Tian; Jingdian Liu; Kai Zhao; Junwen Wang; Wei Jiang; Kai Shu; Ting Lei
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

3.  Comparative Analysis of the MRI Characteristics of Meningiomas According to the 2016 WHO Pathological Classification.

Authors:  Juan Yu; Fan-Fan Chen; Han-Wen Zhang; Hong Zhang; Si-Ping Luo; Guo-Dong Huang; Fan Lin; Yi Lei; Liangping Luo
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

4.  Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.

Authors:  Katherine Belanger; Timothy H Ung; Denise Damek; Kevin O Lillehei; D Ryan Ormond
Journal:  BMC Cancer       Date:  2022-04-07       Impact factor: 4.430

5.  A Retrospective Evaluation of the Retrosigmoidal Approach for Petroclival Meningioma Surgery and Prognostic Factors Affecting Clinical Outcome.

Authors:  Waseem Masalha; Dieter Henrik Heiland; Christine Steiert; Marie T Krueger; Daniel Schnell; Christian Scheiwe; Anca-L Grosu; Oliver Schnell; Juergen Beck; Juergen Grauvogel
Journal:  Front Oncol       Date:  2022-04-01       Impact factor: 5.738

Review 6.  Radiation therapy for atypical and anaplastic meningiomas: an overview of current results and controversial issues.

Authors:  Lorenzo Vagnoni; Sami Aburas; Martina Giraffa; Ivana Russo; Vito Chiarella; Sergio Paolini; Paolo Tini; Giuseppe Minniti
Journal:  Neurosurg Rev       Date:  2022-06-04       Impact factor: 2.800

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.